Sarcoma and GIST Cancer TRDG: Meetings and Minutes


  1. The current status of translational research efforts at FCCC and Temple in the particular disease site including the status of Investigator-initiated trials and opportunities based on science and feasibility.
  2. Opportunities for collaboration based on existing ongoing activities or through knowledge of developments in the field.
  3. To exchange information regarding funding opportunities.
  4. To consider multidisciplinary programmatic efforts that may be supported by P01s or SPOREs.
  5. To discuss progress that is being made through more focused presentations by specific investigators or subgroups.
  6. To take full advantage of institutional capabilities and resources in terms of genomics, tissues, CTO, and to integrate across programmatic efforts, basic or clinical research activities and tumor boards.
  7. To bring in additional investigators including lab members/trainees involved in translational research.

The TRDGs strive to recognize and develop opportunities for collaborative translational research directions by providing a focused forum for exchange of information among a diverse group of stake-holders interested in a particular disease site. Before each meeting, depending on the particular expertise, participants are asked to review/be prepared to discuss the current disease site early phase investigational protocols at FCCC, the potential opportunities in industry with available targeted agents, potential collaborations with other institutions that have activated protocols with novel agents, specific molecular targets or signaling pathways for the disease site at FCCC, resistance mechanisms, potential biomarkers that can be incorporated into protocols, and the major open questions for the disease site or other more general questions in the field that could be addressed for the disease site.

  • 10-6-16

    Dr. Jimson D’Souza spoke about “Advances in Translational GIST Cancer Research”. He described PDX models and novel kinase targets. He has implanted 18 cases over the last couple of years. Several are growing tumors and he described gene changes in different models as well as emerging information on resistance to therapy. A question was raised as to whether it is known if more heavily treated patients are easier to make PDX models from. Dr. D’Souza mentioned that some of the models have been serially passaged in mice and he described collaborations that will assist in molecular characterization of models. There was additional discussion about different patterns of mutations in GIST and drug targeting approaches.

  • 5-11-16

    Dr. El-Deiry spoke about R21 RFA in clinical and translational studies. Dr. Martin Belinsky spoke about “NF1 deficiency in GIST”. He started with whole exome sequencing (WES) of a case supported by Sarcoma Foundation of America. He described the ‘omic’ efforts in the GIST group... Expand

  • 3-9-16

    Dr. Meg von Mehren spoke about PARP inhibitors in sarcoma. Imatinib resistance lab work led to insights as far as c-KIT mutations and patterns with different other drugs. ... Expand

  • 10-29-15

    Dr. Sujana Movva currently has 3 investigator-initiated trials including a Takeda mTOR1/2 inhibitor for sarcoma with PTEN loss (40%), a collaboration with Dana Farber on CDK4 inhibit plus mTOR in liposarcoma (80% overexpress CDK4), and an EPCRS grant to look at biomarkers of sensitivity to doxorubicin in soft tissue sarcomas... Expand

  • 4-28-15

    Dr. Lori Rink spoke about imatinib resistance in GIST with primary and secondary resistance. There is an effort to establish PDX models, efforts to study role of KRAB-ZNFs in rapid response to imatinib, and MK-2206 Akt inhibitor studies. 4 PDX models have been established since March. A liver metastasis from a non-responder was established.  All from surgical specimens. All are in progress as far as in vivo growth. They have in the past tried to grow cell lines but it is difficult due to slow growth of the tumors... Expand

  • 2-25-15

    Dr. El-Deiry introduced the TRDG, welcomed the attendees at the meeting and went over the standing Agenda that was circulated in the initial invitation and in the email with the schedule for the meeting.  It was discussed that various meeting formats going forward would be used including the round-table as well as more focused in depth presentations by individuals or collaborators... Expand